GlassScriptPhysician profile
Christopher M Bohyer
NPI 1285757856
$19,995.01
in general payments reported to CMS, 2019-2025
43 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,048 · 2020: $2,170 · 2021: $3,137 · 2022: $3,795 · 2023: $2,595 · 2024: $2,732 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,662 · Consulting Fee: $175 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,661.64 |
| Consulting Fee | $175.00 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,821.73 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $2,236.27 | 2019-2025 | |
| Ucb, INC. | $1,731.42 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $1,294.18 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,191.65 | 2019-2025 | Tremfya |
| Vyne Pharmaceuticals INC. | $1,092.56 | 2020-2021 | |
| Amgen INC. | $998.08 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $890.75 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $833.71 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Genzyme Corporation | $725.62 | 2019-2025 | |
| Pfizer INC. | $642.83 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $587.58 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $585.32 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $512.59 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $438.44 | 2019-2025 | Nemluvio, Aklief, Epsolay |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bohyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.